Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.
In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.
Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.
Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.
LeMaitre Vascular (Nasdaq:LMAT) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close. The company will host a conference call at 5:00 PM EDT on the same day to discuss quarterly results, business highlights, and future outlook.
Investors can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available both live and for replay through the company's investor relations website at ir.lemaitre.com.
LeMaitre Vascular (NASDAQ:LMAT) announced that its President, David Roberts, will present at the Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13, 2024, at 5:00 PM PDT and will take place at the Encore at the Wynn Hotel in Las Vegas, NV.
LeMaitre Vascular (NASDAQ:LMAT) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, after market close. The company will host a conference call at 5:00 PM EDT on the same day to discuss quarterly results, business highlights, and future outlook. Interested participants can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available both live and for replay through the company's investor relations website.
LeMaitre Vascular (Nasdaq: LMAT) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team is scheduled to deliver their presentation on Tuesday, April 8, 2025, at 3:45 PM EDT. This virtual event represents an opportunity for investors and healthcare industry stakeholders to gain insights into LeMaitre's operations and strategic initiatives.
LeMaitre Vascular (Nasdaq:LMAT) has announced its management team's participation in three major investor conferences this March 2025:
- The 37th Annual ROTH Conference on March 17 at The Laguna Cliffs Marriott in Dana Point, CA, with a presentation scheduled for 4:00 PM PDT
- The KeyBanc Healthcare Forum, a virtual event on March 19, presenting at 1:30 PM EDT
- The Oppenheimer 35th Annual Healthcare MedTech & Services Conference, another virtual event on March 20, with a presentation time of 10:00 AM EDT
LeMaitre (LMAT) reported strong Q4 2024 financial results with sales reaching $55.7 million, up 14% year-over-year. The company demonstrated robust performance with operating income increasing 26% to $12.9 million and earnings per diluted share growing 30% to $0.49.
Key growth drivers included grafts (+23%), carotid shunts (+14%), and catheters (+12%). Regional sales showed strong momentum with APAC up 21%, EMEA 18%, and Americas 12%. Gross margin improved to 69.3%, up 121 basis points from Q4 2023.
The company announced significant financial moves, including a 25% increase in quarterly dividend to $0.20/share, issuance of $172.5 million in Convertible Senior Notes due 2030, and authorization of a $75 million share repurchase program. Cash position strengthened to $299.7 million. Additionally, XenoSure patches received Chinese cardiac approval in December.
LeMaitre Vascular (LMAT) has scheduled its Q4 2024 earnings release for Thursday, February 27, 2025, after market close. The company will host a conference call at 5:00 PM EST on the same day to discuss financial results, business highlights, and company outlook. Interested parties can access the live call by registering online, and all registrants will receive dial-in information and a PIN. Additionally, an audio webcast will be available live and for replay through the company's investor relations website.
LeMaitre Vascular (Nasdaq: LMAT) has announced the pricing of $150 million in 2.50% Convertible Senior Notes due 2030. The notes will be sold to qualified institutional buyers with settlement scheduled for December 19, 2024. The company granted initial purchasers an option to buy an additional $22.5 million in notes.
The notes will accrue interest at 2.50% annually, payable semi-annually, and mature on February 1, 2030. The initial conversion rate is 8.3521 shares per $1,000 principal amount, representing a conversion price of $119.73 per share - a 30% premium over the current stock price of $92.10. The net proceeds, estimated at $145.9 million (or $167.8 million if additional notes are purchased), will be used for working capital and general purposes, including potential acquisitions.
LeMaitre Vascular (LMAT) announced plans to offer $150 million in Convertible Senior Notes due 2030, with an additional $22.5 million option for initial purchasers. The notes will be senior, unsecured obligations with semi-annual interest payments, convertible into cash, LMAT common stock, or a combination at LeMaitre's discretion.
The notes will be redeemable after February 5, 2028, if LMAT's stock price exceeds 130% of the conversion price. Noteholders can require LeMaitre to repurchase notes if fundamental changes occur. The company plans to use proceeds for working capital and general purposes, including potential acquisitions. The offering is to qualified institutional buyers under Rule 144A.